Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance

BIO-TECHNE CorpTrade
Vanguard Real Estate Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Vanguard Real Estate Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vanguard Real Estate Index Fund ETF trades at $95.14. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Real Estate Index Fund ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.

TECHVNQ
Market Cap
$11.34B
Sector
Health
52-Week High
$72.48$100.95
52-Week Low
$43.31$87.00
Enterprise Value
$11.36B
Dividend Yield
0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.

The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.

Vanguard Real Estate Index Fund ETF

VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates impacting real estate valuations, though some analysts see mispricing opportunities in quality REITs during this downturn. Recent institutional selling activity and mixed media sentiment reflect ongoing sector challenges.

The outlook remains cautious as high rates pressure REIT valuations, but selective opportunities exist in digital infrastructure and quality names. Key risks include prolonged high interest rates, economic slowdowns affecting property demand, and competition from alternative income ETFs. Investors should focus on REITs with strong fundamentals and growth potential in evolving sectors like AI infrastructure.

Returns comparison

Trailing returns across standard periods

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH

About Vanguard Real Estate Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.

Read more on VNQ